Blogging Equity Patents Pricing 
Startup Professionals Musings
MAY 1, 2021
Those at the other extreme don’t look up from the grindstone long enough to notice whether all their work is producing sweat equity or just sweat. You have figured out how to undercut your competitor’s price, and still hold your margin. Incorporate, register your domain name, trademarks, and copyrights, then patent if possible.
Both Sides of the Table
AUGUST 14, 2017
I read commentary or Twitter or blogs and realize that there are also strongly held convictions that there are these evil VCs who do terrible things to mostly altruistic founders. Boards are not appointed to be founder-friendly lapdogs for the 1–3 founders who start companies and usually own the largest equity positions in the company.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Startup Professionals Musings
MAY 18, 2013
Those at the other extreme don’t look up from the grindstone long enough to notice whether all their work is producing sweat equity or just sweat. You have figured out how to undercut your competitor’s price, and still hold your margin. Incorporate, register your domain name, trademarks, and copyrights, then patent if possible.
Startup Professionals Musings
APRIL 29, 2012
Those at the other extreme don’t look up from the grindstone long enough to notice whether all their work is producing sweat equity or just sweat. You have figured out how to undercut your competitor’s price, and still hold your margin. Incorporate, register your domain name, trademarks, and copyrights, then patent if possible.
Startup Professionals Musings
NOVEMBER 12, 2010
Those at the other extreme don’t look up from the grindstone long enough to notice whether all their work is producing sweat equity or just sweat. You have figured out how to undercut your competitor’s price, and still hold your margin. Incorporate, register your domain name, trademarks, and copyrights, then patent if possible.
Xconomy
JUNE 3, 2016
Merck also saw some expected fruits of its 2014 big-ticket acquisition of Cubist Pharmaceuticals wither away this week, as the Supreme Court wouldn’t reverse a decision that shaved years off the patent life of the top-selling antibiotic daptomyicin (Cubicin). The drug has a list price of $69,350 per patient, per year.
Startup Professionals Musings
SEPTEMBER 30, 2013
It doesn’t prove your business model of pricing, distribution, and support. File a provisional patent, register a trademark, and reserve your company domain names. Investors like to see that you have committed personal funds as well as “sweat equity,” and they like to see real progress at this level. Show personal investment.
Expert insights. Personalized for you.
160 
Let's personalize your content